Positive Quality Intervention: Osimertinib (Tagrisso®) In EGFR Positive Non-Small Cell Lung Cancer

Description: Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion or exon 21 L858R and with EGFR T790M mutation positive disease with progression on/after EGFR tyrosine kinase inhibitor- based therapy. This PQI aims to provide guidance for initiating therapy with osimertinib.

Background: Osimertinib is a third-generation tyrosine kinase inhibitor that irreversibly binds to mutated EGFR, specifically to T790M, exon 21 L858R, and exon 19 deletion. Patients with EGFR mutation are seen to have a stronger response when treated with EGFR mutation directed therapy than the standard doublet chemotherapy. When available, multiplexed genetic sequencing panels are preferred over multiple single gene tests. EGFR mutations are more common in patients with East Asian ethnicity, no history of smoking, adenocarcinoma histology, and of female gender. However, any individual diagnosed with NSCLC may have an EGFR mutation regardless of race, gender, or smoking status and testing is imperative. EGFR mutations are found in ~10-23% in patients with adenocarcinomas of the lung.

The FLAURA study found that osimertinib had a longer PFS when compared to erlotinib and gefitinib, 18.9 months vs 10.2 months, respectively. The rate of ≥ grade 3 adverse events were lower in the osimertinib arm, 35% vs 45%. Most common adverse events (any grade): diarrhea (41% to 58%), rash (34% to 58%), dry skin (23% to 36%), nail toxicity (22% to 35%), and stomatitis (15% to 29%).

The BLOOM study evaluated the use of osimertinib in patients with EGFR mutation-positive advanced NSCLC who had progressed on prior EGFR-TKI therapy and had leptomeningeal disease. The BLOOM study included both T790M positive and T790M unselected patients. Patients were given osimertinib at an off-label increased dose of 160mg once daily with a median duration of response of 8.3 months.

The ADAURA study evaluated the use of osimertinib in patients with EGFR mutation-positive stage 1B, II, or IIIA NSCLC with complete resection. Data was released early due to overwhelming efficiency. An 80% reduction in risk of recurrence/death across as stages of disease studied at the 3 year mark of this study.

PQI Process:
Upon receipt of an osimertinib prescription:
- Review EGFR mutational testing, including T790M, exon 21 L858R, and exon 19 deletion
- Verify the dose/frequency is correct
  - Dosing: 80 mg orally once daily with or without food
  - 160 mg orally once daily for leptomeningeal disease (off-label)
  - If patient cannot swallow the osimertinib tablet whole, the tablet can be dissolved in water
  - Stir tablet in 60 mL of water - tablet will not completely dissolve but stir until dispersed into small pieces, rinse the container used to dissolve the tablet with 120mL - 240mL of water and drink immediately
- Review patient medication list for possible drug-drug interactions
  - Strong CYP3A4 inducer: increase osimertinib starting dose to 160 mg once daily
  - Strong CYP3A4 inhibitors: No dos reduction, but monitor for adverse drug reactions

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
PQI Process Continued:

- Evaluate patient for the need for baseline cardiac monitoring
  - Monitor LVEF in patients with cardiac risk factors
  - Monitor QTc and electrolytes in patients with history of QTc prolongation or on other QTc prolonging medications
    - QTc >500 msec on at least 2 separate ECGs: hold osimertinib, resume at 40 mg/d when QTc <481 msec or patient returns to baseline QTc
    - QTc with life threatening arrhythmias: permanently discontinue
- Ensure supportive care is addressed (See Supplemental Information section)

Patient Centered Activities:

- Patient Education
  - Provide Oncology Chemotherapy Education (OCE) sheet and Oncology Chemotherapy Education Supplemental Sheet
  - Instruct patient to report any adverse events, such as rash, nail changes, diarrhea, dry or itchy skin, nausea/vomiting, mouth sores, or inflammation
  - Ensure patient has access to supportive medications
    - Anti-nausea: ex. metoclopramide, prochlorperazine, or 5-HT3 receptor antagonist
    - Anti-diarrheal: ex. loperamide
  - Instruct patient to avoid sun exposure when possible. If unavoidable, utilize sunscreen
- Medication Access Assistance
  - Co-Pay Foundation assistance
  - AstraZeneca Access 360 Patient Savings Program
  - AZ&ME AstraZeneca Prescription Savings Program

References:

1. Tagrisso (osimertinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals.

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
Supplemental Information

Diarrhea management - The onset of diarrhea is typically within the first four weeks

<table>
<thead>
<tr>
<th>Grade 1 Diarrhea (Mild)</th>
<th>Grade 2 Diarrhea (Moderate)</th>
<th>Grade 3 Diarrhea (Severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase of &lt;4 stools per day over baseline</td>
<td>Increase of 4-6 stools per day over baseline</td>
<td>Increase of ≥7 stools per day over baseline</td>
</tr>
<tr>
<td>Start loperamide*</td>
<td>Continue loperamide*</td>
<td>Continue loperamide*</td>
</tr>
<tr>
<td>Continue osimertinib</td>
<td>Hold osimertinib if diarrhea does not improve after 48 hours</td>
<td>Hold osimertinib, when diarrhea has improved to grade 1, restart at reduced dose</td>
</tr>
<tr>
<td></td>
<td>When diarrhea has improved to grade 1, restart at original dose</td>
<td>**Permanently discontinue if diarrhea does not return to grade 1 within 14 days</td>
</tr>
</tbody>
</table>

*Loperamide dosing: 4 mg followed by 2 mg after each loose stool (up to 20 mg daily)

Rash management

<table>
<thead>
<tr>
<th>Grade 1 Rash (mild)</th>
<th>Grade 2 Rash (Moderate)</th>
<th>Grade 3 Rash (Severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covering &lt;10% of BSA</td>
<td>Covering 10-30% of BSA</td>
<td>Covering &gt;30% of BSA</td>
</tr>
<tr>
<td>Topical corticosteroid: triamcinolone 0.1% or hydrocortisone 2.5% daily or twice daily</td>
<td>Topical corticosteroid: triamcinolone 0.1% or hydrocortisone 2.5% twice daily</td>
<td>Topical corticosteroid: clobetasol 0.05% cream twice daily</td>
</tr>
<tr>
<td>± topical antibiotic: clindamycin 1% gel or lotion (alcohol free preparation)</td>
<td>AND oral antibiotic: 4-week course of an oral tetracycline antibiotic</td>
<td>AND oral antibiotic: 4-week course of an oral tetracycline antibiotic</td>
</tr>
<tr>
<td>Continue osimertinib</td>
<td>Continue osimertinib, if rash is intolerable osimertinib can be held</td>
<td>Hold osimertinib, resume at 50% of original dose when patient has improved to ≤ grade 2</td>
</tr>
</tbody>
</table>

- Rash or acne with osimertinib was found to occur at a lower rate when compared with standard EGFR-TKI therapy (osimertinib any grade: 58%, grade ≥3 1%; standard EGFR-TKI any grade: 78%, grade ≥3: 7%)
- Due to the low frequency of acneiform rash, prophylactic management is not recommended, patient should contact their provider if toxicities appear. The onset of rash is typically within the first two weeks
- Pruritus
  - Grade 1-2:
    - Continue osimertinib unless symptoms are intolerable
    - Consider: topical antipruritic and oral antihistamine
  - Grade 3:
    - Hold osimertinib, resume or reduce dose when patient has improved to ≤ grade 2
    - Consider: topical oral antihistamine, GABA agonist, aprepitant, or doxepin

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.